Recent Updates on the Therapeutic Potential of HER2 Tyrosine Kinase Inhibitors for the Treatment of Breast Cancer.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Current Cancer Drug Targets

• Publication date

  2017-06-23

• Fields of study

  Medicine

• Identifiers
  DOI 10.2174/1568009617666170623122213PMID 28669349
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Emerging Targeted and Multimodal Therapeutic Strategies in Breast Cancer: A Comprehensive Review

  2026cites this paper
• Tucatinib in the treatment of HER2-overexpressing gastrointestinal cancers: current insights and future prospects

  2025cites this paper
• HER2-targeted therapies in cancer: a systematic review

  2024cites this paper
• Unveiling the Phytochemical Profile and In-silico Studies on Bioactive Compounds from Falconeria insignis Royle against Various Target Proteins: A Computational Approach

  2024cites this paper
• In-silico based identification of phytochemicals from Houttuynia cordata Thunb. as potential inhibitors for overexpressed HER2 and VEGFR2 cancer genes

  2021cites this paper
• Computational Approaches for the Design of (Mutant-)Selective Tyrosine Kinase Inhibitors: State-of-the-Art and Future Prospects.

  2020cites this paper
• Metastatic heterogeneity of breast cancer: Molecular mechanism and potential therapeutic targets.

  2020cites this paper
• Tumor Necrosis Factor α Blockade: An Opportunity to Tackle Breast Cancer

  2020cites this paper
• HER family in cancer progression: From discovery to 2020 and beyond.

  2020cites this paper
• Tyrosine Kinase Receptors in Oncology

  2020cites this paper
• HER2 Kinase-Targeted Breast Cancer Therapy: Design, Synthesis, and In Vitro and In Vivo Evaluation of Novel Lapatinib Congeners as Selective and Potent HER2 Inhibitors with Favorable Metabolic Stability.

  2020cites this paper
• Oncogenic signaling pathways associated with immune evasion and the resistance to immune checkpoint inhibitors in cancer.

  2019cites this paper
• HER2 inhibition efficiency of 6-amino-2-methyl-2-phenethyl-2H-benzopyran and feasibility of the 64Cu-labeled benzopyran derivative in cancer diagnosis

  2019cites this paper
• EP300 and SIRT1/6 Co-Regulate Lapatinib Sensitivity Via Modulating FOXO3-Acetylation and Activity in Breast Cancer

  2019cites this paper
• Frequency of I655V SNP of HER-2/neu in colorectal cancer: a study from India

  2019cites this paper
• Genomic alterations associated with HER2+ breast cancer risk and clinical outcome in response to trastuzumab

  2018cites this paper
• Targeted agents for HER2-positive breast cancer in older adults: current and future perspectives

  2018cites this paper